Clinical trials: Vascular Tumor
Multiple Myeloma
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
The purpose of this study is to find out whether giving a single dose of tocilizumab before treatment with ramantamig can help prevent or reduce the severity of cytokine release syndrome (CRS) within 28 days from ramantamig…
- Trial name
- TRI Pro (NCT07589634)
- Testing
- Ramantamig, Tocilizumab
- Where
- 38 sites in United States, Argentina and 7 more
- Volunteers
- 230 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.
- Trial name
- NCT03943472
- Testing
- Anti-BCMA CAR-T cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma
The purpose of this open-label, non-randomized trial is to assess the safety and effectiveness of PXD101, both alone and in combination with dexamethasone, in patients with advanced multiple myeloma.
- Trial name
- NCT00131261
- Testing
- PXD101, Dexamethasone
- Where
- 10 sites in United States, Denmark and 2 more
- Volunteers
- 25 people
- Sponsor
- Valerio Therapeutics
Multiple Myeloma
A Clinical Study of SHR-9539 in Patients With Multiple Myeloma
This study is a multicenter, open-label, dose-escalation/dose-expansion clinical Phase I trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy profile of SHR-9539 Injection in…
- Trial name
- NCT06484777
- Testing
- SHR-9539 for injection
- Where
- China
- Volunteers
- 138 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Malignant Lymphoma, Multiple Myeloma
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation
A randomized, comparative, double-blind trial of pentaisomaltose and dimethyl sulphoxide for cryoprotection of hematopoietic stem cells in subjects with multiple myeloma or malignant lymphoma with a need for autologous…
- Trial name
- NCT05545202
- Testing
- Pentaisomaltose
- Volunteers
- 150 people
- Sponsor
- Pharmacosmos A/S
Multiple Myeloma
A Retreatment Study With Bortezomib for Multiple Myeloma
The purpose of this study is to monitor such factors as a past history, a previous history of drug use, the degree of response to initial treatment, the frequency of previous therapies, age, Eastern Cooperative Oncology Group…
- Trial name
- NCT01030302
- Testing
- bortezomib
- Volunteers
- 56 people
- Sponsor
- Janssen Korea, Ltd., Korea
Sarcoma, Kaposi, HIV Infections
SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment
The purpose of this study is to test the effectiveness of SU5416 in patients with AIDS-related Kaposi's sarcoma (KS).
- Trial name
- NCT00005931
- Testing
- SU5416
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- SUGEN
Relapse and/or Refractory Multiple Myeloma
A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)
The main aim of this study is to see how people with MM respond to previous or current treatment. Participants will be treated according to their clinic's standard practice.
- Trial name
- NCT04135963
- Where
- 8 sites in Portugal
- Volunteers
- 62 people
- Sponsor
- Takeda
Cancer, Advanced Cancer
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population.
- Conditions
- Cancer, Advanced Cancer, Locally Advanced Carcinoma, Metastatic Solid Tumor
- Trial name
- NCT06440005
- Testing
- AGX101
- Where
- 7 sites in United States
- Volunteers
- 80 people
- Sponsor
- Angiex, Inc.
Immunotherapy, Multiple Myeloma
Clinical Study of the Safety and Efficacy of BCMA CAR-NK
The goal of this clinical trial is to study of the Safety and Efficacy of Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK) in Patients with Relapsed/Refractory Multiple Myeloma Primary Endpoints: To…
- Trial name
- NCT05652530
- Testing
- Chimeric Antigen Receptor NK Cell Injection Targeting BCMA (BCMA CAR-NK)
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Shenzhen Pregene Biopharma Co., Ltd.
Multiple Myeloma, Lymphoma, Non-Hodgkin's
AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF Alone
This Phase 2 study was designed to assess the safety and hematological activity of AMD3100 (plerixafor) in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM) who were predicted to be unable to mobilize ≥2*10^6…
- Trial name
- NCT00395967
- Testing
- G-CSF plus plerixafor
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Genzyme, a Sanofi Company
Solid Tumors, Lymphoma, Non-Hodgkin
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)
The study will evaluate the safety, tolerability, maximum administered dose, and dose limiting toxicity of SCH 727965 administered as an intravenous infusion on Days 1, 8 and 15 of each 28 day cycle in participants with solid…
- Conditions
- Solid Tumors, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic. B-Cell
- Trial name
- NCT00871663
- Testing
- SCH 727965
- Volunteers
- 123 people
- Sponsor
- Merck Sharp & Dohme LLC
Sarcoma, Kaposi, HIV Infections
A Study of Tecogalan Sodium
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
- Trial name
- NCT00002342
- Testing
- Tecogalan sodium
- Where
- United States
- Sponsor
- Daiichi Pharmaceuticals
Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia
Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of AZD4573 in subjects with relapsed or refractory haematological malignancies.
- Conditions
- Relapsed or Refractory Haematological Malignancies Including, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia
- Trial name
- NCT03263637
- Testing
- AZD4573
- Where
- 12 sites in Germany, Netherlands and 1 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Relapsed/Refractory Multiple Myeloma
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
This study is a first-in-human, Phase 1, open-label study that will evaluate safety and anti-myeloma activity of ISB 2001 in participants with relapsed/refractory multiple myeloma (R/R MM).
- Trial name
- NCT05862012
- Testing
- ISB 2001
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 200 people
- Sponsor
- Ichnos Sciences SA
Waldenstrom's Macroglobulinemia
Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401
An extension study for patients who complete 24 weeks of IMO-8400 on study 8400-401.
- Trial name
- NCT02363439
- Testing
- IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly
- Volunteers
- 5 people
- Sponsor
- Idera Pharmaceuticals, Inc.
Multiple Myeloma, Waldenstrom Macroglobulinemia
Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies
The purpose of this study is to determine the maximum tolerated dose (MTD), activity, and safety of oprozomib in patients with hematologic malignancies.
- Trial name
- NCT01416428
- Testing
- oprozomib
- Where
- 19 sites in United States
- Volunteers
- 210 people
- Sponsor
- Amgen
Multiple Myeloma, Neoplasms, Plasma Cell
A Study of Ninlaro in Real World Clinical Practice in China
The main purpose of this study is to collect additional safety information of ixazomib citrate (Ninlaro) when used to treat multiple myeloma in real world clinical practice in China.
- Trial name
- NCT04328662
- Where
- 28 sites in China
- Volunteers
- 482 people
- Sponsor
- Takeda
Multiple Myeloma
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT05007418
- Testing
- STI-1492
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sorrento Therapeutics, Inc.
Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
The purpose of this study is to evaluate the safety, pharmacokinetics, immunogenicity, and efficacy of zilovertamab vedotin given intravenously (IV) across a range of dose levels in participants with previously treated…
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT03833180
- Testing
- Zilovertamab vedotin
- Where
- 14 sites in United States
- Volunteers
- 91 people
- Sponsor
- VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.